Seeking Alpha

Progenics Pharmaceuticals +21% on NDA acceptance

|About: Progenics Pharmaceuticals, ... (PGNX)|By:, SA News Editor

Progenics Pharmaceuticals (NASDAQ:PGNX) announces that the FDA has accepted for review its New Drug Application for rare neuroendocrine tumor treatment Azedra.

The FDA also granted the request for priority review and set the PDUFA date for April 30. 

Progenics shares are up 20.5% premarket.  

Try Seeking Alpha PREMIUM for unlimited analysis on PGNX